DTIL (Precision BioSciences Inc.) stock: $6.67, $184.1M market cap, $87.5M cash, $96.6M EV, $253.3M fully diluted market cap. Next expected readout: Dec-26. Lead program: PBGENE-DMD (IV) (Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD), Phase 2. Data from Fully Diluted's biotech stocks database.
Balance sheet
| Cash | $87.5M |
|---|
| Debt | $0.0M |
|---|
| Net cash | $87.5M |
|---|
| Enterprise value | $96.6M |
|---|
| Basic shares | 26.4M shares |
|---|
| Fully diluted shares | 38.0M shares |
|---|
| Fully diluted market cap | $253.3M |
|---|
| Cash per share | $3.31 |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading DTIL daily closes…
Loading price history…
Upcoming catalysts
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|
| Jan 12 - Feb 23 | PBGENE-HBV | Phase 1 | HEPATITIS B CHRONIC | — |
| Dec 13, 2029 - Jan 24, 2030 | PBGENE-DMD (IV) | Phase 2 | Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD | Q4 2026 |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets
PBGENE-HBV
Phase 1 · Active Modality: in vivo gene editing (ARCUS, LNP-delivered)
Target HBV cccDNA
Indications- Chronic hepatitis B (HBV) (Phase 1)
Status note Wholly owned in vivo ARCUS gene-editing program designed to eliminate covalently closed circular DNA (cccDNA), the source of HBV replication. Global first-in-human Phase 1/2a ELIMINATE-B trial enrolling at sites in Hong Kong, New Zealand, the U.S. and Moldova, expanding to the U.K.
PBGENE-DMD
Phase 1 · Active Modality: in vivo gene editing (ARCUS, AAV-delivered)
Target dystrophin gene (exon 45-55 excision)
Indications- Duchenne muscular dystrophy (DMD) (Phase 1)
Status note Wholly owned development candidate for DMD: two complementary ARCUS nucleases in a single AAV excise exons 45-55 of the dystrophin gene, restoring near full-length dystrophin protein expression. Phase 1/2 FUNCTION-DMD trial in ambulatory boys ages 2-7 with mutations between exons 45 and 55; two sites active (Arkansas Children's, Washington University). FDA Rare Pediatric Disease designation (Jun 2025), Orphan Drug Designation (Jul 2025), Fast Track (Feb 2026); PRV-eligible.
Azer-cel
Phase 1 · Active Modality: cell therapy (allogeneic CAR-T)
Aliases azercabtagene zapreleucel
Partnerships Oncology rights licensed to Imugene Limited/Imugene US (Aug 2023; covers up to three additional research candidates). Autoimmune and non-cancer rights licensed to TG Therapeutics (Jan 2024; $10M upfront, up to $288.6M milestones; $7.5M clinical milestone achieved Mar 2026).
Indications- Diffuse large B-cell lymphoma (DLBCL) (Phase 1)
- Progressive multiple sclerosis (Phase 1)
Status note Allogeneic CAR-T therapy. Imugene continues development in DLBCL with written FDA guidance aligned on the registrational pathway (dosing, population, endpoints, manufacturing). TG Therapeutics evaluating azer-cel in a Phase 1 trial in progressive multiple sclerosis.
PBGENE-3243
Preclinical · Active Modality: in vivo gene editing (mitochondria-targeted ARCUS)
Target mutant mitochondrial DNA (m.3243)
Status note Wholly owned candidate for m.3243-associated mitochondrial disease: mitochondria-targeted ARCUS nucleases designed to eliminate mutant mitochondrial DNA and shift heteroplasmy. Development paused to prioritize PBGENE-HBV and PBGENE-DMD.
ECUR-506
Stage not disclosed · Active Modality: in vivo gene editing (ARCUS gene insertion)
Target OTC gene (gene insertion)
Partnerships Developed by iECURE, Inc. under a development and license agreement (Aug 2021); Precision eligible for milestones and mid-single to low-double digit royalties; iECURE uses Precision's PCSK9-directed ARCUS nuclease.
Indications- Neonatal onset ornithine transcarbamylase (OTC) deficiency (Stage not disclosed)
Status note ARCUS-mediated targeted gene insertion approach for neonatal onset OTC deficiency. OTC-HOPE study ongoing in the U.K., U.S., Australia and Spain; FDA Regenerative Medicine Advanced Therapy (RMAT) designation. FDA alignment reached on primary/key secondary endpoints, comparators and study size that could support a BLA.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.